| EMA number | EMEA/H/C/002208 |
| ATC code | M04AX02 |
| Authorisation | 8 January 2013 |
| Withdrawn | 30 June 2016 |
| Revision | 3 |
Krystexxa is indicated for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.